Pyrimidoindole Compounds for Progenitor T Cell Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current adoptive T cell therapies are limited by a lack of suitable patient and tumor-specific T cells, necessitating the development of methods to enhance the production and expansion of therapeutically effective antigen-specific T cells for immunotherapy.
Innovation Solution
The use of pyrimidoindole compounds, such as UM729 and UM171, to differentiate and expand progenitor T cells from hematopoietic progenitor cells, increasing their numbers and promoting their maturation into functional TCR αβ+ T cells, including CD4+ and CD8+ subsets.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional adoptive T cell therapy methods are used, then patient and tumor-specific T cells can be obtained, but the quantity and functionality of T cells are insufficient for effective therapy
Solution Approach 1:
The patent applies preliminary action by using pyrimidoindole compounds during the differentiation stage of hematopoietic progenitor cells into T cells. This early intervention ensures that T cells are generated with enhanced properties before therapy, rather than attempting to boost them after generation. The compounds are introduced at the differentiation phase to pre-condition the T cells for better therapeutic performance.
Solution Approach 2:
The patent employs parameter changes by modifying the chemical environment during T cell differentiation through the addition of pyrimidoindole compounds. These compounds alter the differentiation parameters of hematopoietic progenitor cells, leading to increased T cell quantity and improved functionality. The chemical parameter (presence of pyrimidoindole) directly influences the biological outcome.
2Quantity of substance
If pyrimidoindole compounds are used to differentiate hematopoietic progenitor cells, then the proportion of progenitor T cells increases, but the complexity of the production process increases
Solution Approach 1:
The patent uses parameter changes by introducing pyrimidoindole compounds as a chemical variable in the differentiation medium. This single parameter modification (adding the compound at specified concentrations) simplifies the overall process compared to complex multi-step differentiation protocols, while still achieving increased progenitor T cell proportions.
Data Source
AI summary
This invention relates to methods of producing a population of progenitor T cells comprising differentiating haematopoietic progenitor cells (HPCs) into progenitor T cells in the presence of a pyrimidoindole compound, such as methyl 4-(3-piperidin-1-ylpropylamino)-9H-pyrimido[4,5-b] indole-7-carboxylate (UM729) or (1R,4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine (UM171). The progenitor T cells may be matured, activated and expanded, for example for use in immunotherapy.